BiotechTube
Otsuka Holdings

Otsuka Holdings

4578.T
Tokyo, Japan· Est. 1964

Otsuka Holdings Co., Ltd. is a multinational pharmaceutical and healthcare company founded in 1964, headquartered in Tokyo, Japan. The company has built a strong reputation in central nervous system disorders, with major commercial successes including the antipsychotic Abilify and depression treatment Rexulti. Otsuka operates globally with a focus on innovation in psychiatry, neurology, oncology, and nephrology, maintaining a robust pipeline of novel therapeutics and a commitment to addressing unmet medical needs.

otsuka.com

4578.T · Stock Price

USD 10610.00+2557.00 (+31.75%)
Market Cap: $35.3B

Historical price data

AI Company Overview

Otsuka Holdings Co., Ltd. is a multinational pharmaceutical and healthcare company founded in 1964, headquartered in Tokyo, Japan. The company has built a strong reputation in central nervous system disorders, with major commercial successes including the antipsychotic Abilify and depression treatment Rexulti. Otsuka operates globally with a focus on innovation in psychiatry, neurology, oncology, and nephrology, maintaining a robust pipeline of novel therapeutics and a commitment to addressing unmet medical needs.

PsychiatryNeurologyOncologyNephrologyCardiovascular

Technology Platform

Otsuka specializes in CNS drug discovery with expertise in neurotransmitter systems, digital therapeutics integration, and innovative drug delivery technologies including depot formulations.

Funding History

1
IPOUndisclosedDec 15, 2010

FDA Approved Drugs

4
VOYXACTBLANov 25, 2025
ABILIFY MAINTENA KITNDAFeb 28, 2013
NUEDEXTANDAOct 29, 2010

Opportunities

Significant growth potential in CNS therapeutics through pipeline advancement, digital health integration, and expansion in emerging markets.
The company's expertise in psychiatric disorders positions it well for the growing mental health market.

Risk Factors

Key risks include patent cliffs for major products, intense competition in CNS therapeutics, regulatory challenges in drug development, and pricing pressures from healthcare systems globally.

Competitive Landscape

Competes with major pharmaceutical companies like J&J, BMS, and Pfizer in CNS therapeutics. Differentiates through deep psychiatric expertise, innovative formulations, and strategic focus on underserved patient populations.